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Abstract: 
Alzheimer's disease (AD) is characterized by the brain accumulation of Aβ peptides and by the presence of neurofibrillary tangles. Aβ is believed to play an 
important role in AD and it has been shown that certain flavonoids can affect Aβ production. Recently, it was suggested that the Aβ lowering properties of 
flavonoids are mediated by a direct inhibition the β-secretase (BACE-1) activity, the rate limiting enzyme responsible for the production of Aβ peptides.  Western-
blots and ELISAs were employed to monitor the impact of flavonoids on amyloid precursor protein processing and Aβ production. A cell free chemoluminescent 
assay using human recombinant BACE-1 was used to assess the effect of flavonoids on BACE-1 activity. The effect of flavonoids on NFκB activation was 
determined by using a stable NFκB luciferase reporter cell line. Molecular docking simulations were performed to predict the binding of flavonoids to the BACE-1 
catalytic site. Real time quantitative PCR was used to determine the effect of flavonoids on BACE-1 transcription. We show in a cell free assay that flavonoids are 
only weak inhibitors of BACE-1 activity. Docking simulation studies with different BACE-1 structures also suggest that flavonoids are poor BACE-1 inhibitors as 
they appear to adopt various docking poses in the active site pocket and have weak docking scores that differ as a function of the BACE-1 structures studied. 
Moreover, a weak correlation was observed between the effect of flavonoids on Aβ production in vitro and their ability to lower BACE-1 activity suggesting that 
the Aβ lowering properties of flavonoids in whole cells are not mediated via direct inhibition of BACE-1 activity. We found however a strong correlation between 
the inhibition of NFκB activation by flavonoids and their Aβ lowering properties suggesting that flavonoids inhibit Aβ production in whole cells via NFκB related 
mechanisms. As NFκB has been shown to regulate BACE-1 expression, we show that NFκB lowering flavonoids inhibit BACE-1 transcription in human neuronal 
SH-SY5Y cells. Altogether, our data suggest that flavonoids inhibit Aβ and sAPPβ production by regulating BACE-1 expression and not by directly inhibiting 
BACE-1 activity. 
 
 
 
Background: 
Alzheimer’s disease (AD) is a major health concern among the aging 
population and is the most prevalent form of dementia. While the cause of the 
disease remains uncertain, the extracellular senile plaques and the intracellular 
neurofibrillary tangles constitute the two major neuropathological hallmarks 
present in the brains of AD patients. Neurofibrillary tangles contain 
hyperphosphorylated microtubule-associated protein tau, while senile plaques 
contain a core of β-amyloid (Aβ) peptides. Although the central role of Aβ 
remains to be proven in clinical trials, data accumulated during the past two 
decades place Aβ peptides and in particular soluble forms of the peptide as 
being the main molecule triggering the pathological cascade that eventually 
leads to AD and initiates tau pathology [1]. Aβ peptides are derived from the 
cleavage of the β-amyloid precursor protein (APP) by β- and γ-secretases. The 
major β-secretase is an aspartyl protease termed BACE-1 (β-site APP cleaving 
enzyme) [2-4]. BACE-1 cleaves APP within the extracellular domain of APP, 
resulting in the secretion of the large ectodomain (APPsβ) and generating a 
membrane-tethered C-terminal fragment CTFβ or C99 which serves as a 
substrate for γ-secretase [5]. The multimeric γ-secretase complex cleaves at 
multiple sites within the transmembranous CTFβ generating C-terminally 
heterogeneous Aβ peptides ranging between 38 to 43 amino-acid residues in 
length that are secreted [6]. In addition to BACE-1 and γ-secretase, APP can be 
cleaved by α-secretase within the Aβ domain between Lys
16 and Leu
17, 
releasing APPsα and generating CTFα or C83 which is further cleaved by γ-
secretase to generate an N-terminally truncated Aβ termed p3. Genetic ablation 
of BACE-1 completely abolishes Aβ production, establishing BACE-1 as the 
major neuronal enzyme responsible for initiating the amyloidogenic processing 
of APP [7].  
 
Current treatments for AD include cholinesterase inhibitors and glutamate 
antagonists. Although useful, these symptomatic treatments do not stop the 
disease process or prevent neuronal degeneration. There is an on-going need 
for the development of new treatments for AD. It has been suggested that a diet 
rich in polyphenols including flavonoids may have beneficial effects in AD [8]. 
Flavonoids are plant metabolites that are dietary antioxidant, and it has been 
hypothesized that this activity may account for their beneficial effects against 
dementia [9]. The Ginkgo biloba extract EGb761 which contains essentially 
flavonoids (quercetin, kaempferol and isorhamnetin) and terpene lactones 
(ginkgolides A,B,C and bilobalide) has also been suggested to have positive 
effects against dementia and AD [10, 11]. Recently, several flavonoids have 
been shown to regulate Aβ production and it has been suggested that these 
compounds act by directly inhibiting BACE-1 activity [12].  As BACE-1 is the 
rate limiting enzyme responsible for Aβ production and is considered to be a 
prime target for AD, we further investigated whether flavonoids can lower Aβ BIOINFORMATION  open access 
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production in whole cells by directly inhibiting BACE-1 activity. We tested the 
effects of different flavonoids on Aβ production and APP processing using a 
cell line overexpressing human APP and attempted to correlate the Aβ 
lowering activity of the flavonoids with their BACE-1 inhibitory activity. 
Moreover, we investigated the binding affinity of flavonoids for the BACE-1 
catalytic site using thorough docking simulations to determine whether 
flavonoids hold promise as BACE-1 inhibitors. 
 
Methodology: 
Flavonoids: 
Daidzein (4′,7-Dihydroxyisoflavone, 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-
benzopyran-4-one, 7-Hydroxy-3-(4-hydroxyphenyl)chromone), genistein 
(4′,5,7-Trihydroxyisoflavone, 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-
benzopyran-4-one), luteolin (3′,4′,5,7-Tetrahydroxyflavone), kaempferol 
(3,4′,5,7-Tetrahydroxyflavone, 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-
benzopyran-4-one), apigenin (4′,5,7-Trihydroxyflavone), quercetin (2-(3,4-
Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 3,3′,4′,5,6-
Pentahydroxyflavone), α-naphthoflavone (7,8-Benzoflavone), β-
naphthoflavone (5,6-Benzoflavone), acacetin (5,7-Dihydroxy-4′-
methoxyflavone), taxifolin (3,3′,4′,5,7-Pentahydroxyflavanone hydrate), 
PD98059 (2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) were 
obtained from Sigma Chemicals (MO, USA). Aminogenistein (4′-Amino-6-
hydroxyflavone) and baicalein (5,6,7-Trihydroxyflavone) were obtained from 
Calbiochem (EMD Chemicals, CA, USA). 
 
Aβ enzyme-linked immunosorbent assay (ELISA): 
7W CHO cells stably transfected with human APP751 [13] were maintained in 
DMEM (ATCC, VA, USA) medium containing 10% fetal bovine serum 
(Invitrogen, CA, USA), 1X mixture of penicillin/streptomycin/fungizone 
mixture (Cambrex, ME, USA) and 0.3% geneticin (Invitrogen, CA, USA) as a 
selecting agent. Cells were cultured in 96-wells culture plates and treated for 24 
hours with different doses of flavonoids as indicated in the figure legend. All 
flavonoids were diluted in DMSO before being exposed to confluent 7W CHO 
cells so that the final concentration of DMSO in the culture medium was 0.1%. 
The control wells were treated with 0.1% DMSO. Human Aβ1-40 and Aβ1-42 
were analyzed in the culture medium by using commercially available 
sandwich ELISAs (Invitrogen, CA) according to the manufacturer's 
instructions. All experiments were repeated 3-4 times.  
 
Evaluation of APP processing by Western-blots: 
The impact of flavonoids on APP processing was evaluated using 7W CHO 
cells as we previously published [14]. Briefly, confluent 7W CHO cells were 
treated for 24 hours with 10 and 20 μM of flavonoids in 24-well plates. 
Cellular proteins were extracted with 80 μL of ice-cold M-PER Reagent 
(Pierce Biotechnology, Rockford, IL, USA) containing 1mM 
phenylmethanesulfonyl fluoride, 1X of protease cocktail inhibitor (Roche, Inc., 
USA) and 1mM sodium orthovanadate. Samples were sonicated, denatured by 
boiling in Laemmli buffer (Bio-Rad, Hercules, CA, USA) and resolved onto 4–
20% gradient polyacrylamide gels (Bio-Rad, Hercules, CA, USA). After 
electrotransfering onto polyvinylidene difluoride membranes, western-blots 
were immunoprobed with a 1:1000 dilution of an anti-APP C-terminal (751–
770) antibody (EMD Biosciences Inc., San Diego, CA, USA), with an anti-
actin antibody (Chemicon, Temecula, CA, USA) used as a reference antibody 
to ensure that equal amount of proteins were electrotransferred. Additionally, 
sAPPα was detected by Western-blot in the culture medium surrounding 7W 
CHO cells using the antibody 6E10 (Signet Laboratories Inc., MA, USA) 
which recognizes amino acids 1–17 of Aβ and sAPPβ was detected in the 
culture medium using an anti-human sAPPβ antibody (Immuno-Biological 
Laboratories Co. Ltd., Gunma, Japan). 
 
β-secretase activity measurements: 
β-secretase activity was measured using human recombinant BACE-1 
(Calbiochem, CA, USA) with a commercially available chemoluminescent 
assay (Discoverix, CA, USA) following the recommendations of the 
manufacturer. The β-secretase inhibitor IV (BACE IV) inhibitor was used as a 
positive control in the assay and was purchased from EMD Chemicals (CA, 
USA). Briefly, BACE-1 enzymatic reactions were carried out for 2 hours at 
room temperature with 10 ng/μl of BACE-1 recombinant enzyme in 96-well 
plates in a final volume of 100 μl. Chemoluminescent signals were quantified 
on a HTS Synergy multiplate reader from Biotek (VT, USA). 
 
NFκB luciferase activity: 
NFκB activation was quantified using a stable NFκB luciferase reporter cell  
line of HEK293 cells with chromosomal integration of a luciferase reporter 
construct regulated by 6 copies of the NFκB response element (Panomics, CA, 
USA). Cells were grown in DMEM containing 10% serum, 1% 
penicillin/streptomycin/fungizone and 100 μg/ml of hygromycin B. Confluent 
cells were treated with 20 ng/ml of TNFα (Sigma, MO, USA) to induce NFκB 
activation and with a dose range of the different flavonoids for 3 hours. 
Luciferase activity was detected with the Luc-Screen Extended-Glow from 
Applied Biosystems (CA, USA) and a Synergy HT Biotek chemoluminescent 
reader (VT, USA) as we previously described [14]. 
 
Evaluation of BACE-1 transcription: 
Confluent SH-SY5Y cells (ATCC, VA, USA) grown in DMEM/F12 medium 
supplemented with 10% fetal bovine serum and 1X mixture of 
penicillin/streptomycin/fungizone mixture were treated with 20 ng/ml of 
TNFα, or with 20 μM of apigenin, luteolin, quercetin and daidzein  either alone 
or in combination with 20 ng/ml of TNFα for 30 minutes at 37°C, 5% CO2 
(control wells received the same volume of vehicle used to dissolved the 
flavonoids). After 30 minutes of incubation, RNA was extracted as we 
previously described [15]. The quality and purity of the RNA obtained were 
tested on agarose gels and spectrophotometrically at 260 nm and 280 nm. All 
RNA samples had an A260/280 absorbance ratio between 1.9 and 2.1. Real 
time quantitative PCR (RT-qPCR) were performed as we previously described 
[15]. Briefly, to quantify the transcript levels of the BACE-1 gene by RT-
qPCR, a protocol using FastStart TaqMan Prob Master Mix (Roche) reaction 
was performed in duplicates. All reactions contained 2 μL of cDNA (20 ng), 10 
μL of the 2× Master Mix and 0.5 μL of 20 μM of each BACE-1 primer 
(ttcatcaacggctccaact and ctccagggagtcgtcagg), 250 nM of BACE-1 gene 
specific probe (#04688058001), 500 nM reference (HPRT) gene primer mix 
(cgtgattagtgatgatgaaccag and cgagcaagacgttcagtcct), 250nM reference HPRT 
gene probe (# 05046157001) and DEPC-treated water to a final volume of 
20μl. The reaction protocol started with a 2-min activation step at 50°C, a 10 
min template denaturation step at 95°C, followed by 50 cycles of 95°C for 15 
sec and 60°C for 20 sec, BACE-1 mRNA fold change (relative to the 
hypoxanthine-phosphoribosyl-transferase (HPRT) mRNA was calculated as 
previously described [15]. 
 
Molecular docking study of flavonoids: 
Information regarding selected Flavonoids 2D structure was obtained as 
SMILES notation from Pubchem database (http://pubchem.ncbi.nlm.nih.gov/) 
for: Genistein, Quercetin, Taxifolin, Kaemferol, PD98059, Luteolin, Apigenin, 
Daizein, Aminogeneistein, alpha- and beta-napthofalvone. Each of the 2D 
ligand string was converted into 3D conformers using LigPrep tool and each 
conformer was further energy minimized by applying OPLS_2005 force field. 
Low energy conformer for each ligand was retained and subsequently used for 
docking experiments. We used GLIDE XP (eXtra Precision release 2010, 
Schordinger Inc, USA) to perform docking against two different crystal 
structures of BACE-1 from the PDB files 2B8L and 2QMF. The ligand bound 
active site pocket in the two crystal structures were identified and a grid map 
was generated using the centroid of the bound ligand. We used a Vander-Waals 
radius scaling factor of 1.0 and a partial charge cutoff of 0.25 to soften the 
potential of non-polar atoms in the BACE pocket and no other explicit 
constraints were specified. Each docking run samples a variety of poses for the 
ligand in the BACE active site pocket. An energetic and empirical scoring 
criterion is used to rank several thousand docked conformations. The scoring 
algorithm rewards (favorable interactions) or penalizes (unfavorable 
interactions) the Glide XP score (scoring function) which can be used to further 
rank the docked pose. A Van der Waals scaling factor of 0.8 for the ligand was 
used in order to soften the potential for non-polar ligand atoms. We also 
performed a post-dock minimization run to obtain favorable conformations and 
to reduce any strain. We applied a strain correction factor (to account for 
excessive strain due to conformational restriction upon binding to the pocket) 
to the Glide XP score whenever the observed strain energy of bound ligand 
exceeds 4 kcal/mol. A docked pose with a low Glide XP score was considered 
to be the most favorable state and ranked as the top conformer. 
 
Statistical analysis: 
Data were expressed as means ± S.E.M of n experiments. The statistical 
significance of the differences between treatment groups was determined by 
one-way ANOVA and post-hoc comparisons where appropriate using SPSS 
12.0.1 for Windows. The half maximal inhibitory concentration (IC50) for the 
different assays was determined using GraphPad Prism 5 (GraphPad Software, 
Inc., CA, USA). 
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Figure 1: Dose dependent effects of flavonoids on Aβ production. The effect 
of a dose range of flavonoids on Aβ1-40 (A) and Aβ1-42 (B) production was 
investigated using 7W CHO cells overexpressing human APP after 24 hours of 
treatment. ANOVA reveals a significant main effect of the treatments 
(P<0.001) and doses (P<0.001) on both Aβ1-40 and Aβ1-42 production. Post-
hoc comparisons show significant differences for Aβ1-40 production between 
the control conditions and the β-naphthoflavone (P<0.001), kaempferol 
(P<0.04), quercetin (P<0.001), aminogenistein (P<0.001), luteolin (P<0.001), 
apigenin (P<0.001) and acacetin (P<0.001) treatments but no significant 
differences between the control conditions and baicalein, α-naphthoflavone, 
daidzein, genistein, PD98059 and taxifolin (P>0.05) treatments. Post-hoc 
comparisons show significant differences for Aβ1-42 production between the 
control conditions and the β-napthoflavone (P<0.001), quercetin (P<0.001), 
aminogenistein (P<0.001), luteolin (P<0.001) and apigenin (P<0.008) but no 
significant differences between the control conditions and baicalein, α-
naphthoflavone, kaempferol, daidzein, genistein, PD98059, taxifolin and 
acacetin (C). Graph showing a correlation between Aβ1-40 and Aβ1-42 values 
obtained following treatments with different doses of the Aβ lowering 
flavonoids. A strong correlation between Aβ1-40 and Aβ1-42 values was 
observed (Pearson correlation coefficient=0.911; P<0.001) showing that 
flavonoids inhibit Aβ1-40 and Aβ1-42 with similar potency. 
 
Figure 2: Effects of different flavonoids on APP processing in 7W CHO cells 
overexpressing human APP. (A) Effect of a 24 hour treatment with different 
flavonoids (10 and 25 μM) on sAPPβ and sAPPα production by 7W CHO 
cells. Luteolin, apigenin, β-naphthoflavone, quercetin and kaempferol appear to 
reduce sAPPβ production. (B) Effect of a 24 hour treatment with different 
flavonoids at a concentration of 50 μM on sAPPβ and sAPPα production by 
7W CHO cells. An inhibition of sAPPβ production was observed with 
quercetin, taxifolin, kaempferol, PD98059, luteolin, apigenin and β-
naphtoflavone, however genistein, aminogenistein, baicalein and daidzein did 
not impact sAPPβ production. (C) Impact of a 24 hour treatment on APP C-
terminal fragments with different flavonoids at a concentration of 20 μM. A 
reduction in APP-CTFβ production was observed for luteolin, quercetin, 
apigenin whereas an accumulation of APP-CTFα and APP-CTFβ (suggesting 
an impact on γ-secretase activity) was observed for daidzein, aminogenistein 
and genistein. Altogether these data suggest that quercetin, taxifolin, BIOINFORMATION  open access 
- 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 6(6): 229-236 (2011)  232             © 2011 Biomedical Informatics
 
kaempferol, PD98059, luteolin, apigenin and β-naphtoflavone inhibit the β-
cleavage of APP. 
 
 
Figure 3: Effects of flavonoids on BACE-1 activity in a cell free assay. 
ANOVA reveals a significant main effect of the treatment groups across the 
doses tested (P<0.001). Post-hoc comparisons show statistical significant 
BACE-1 activity inhibition across the doses tested for baicalein (P<0.001), 
apigenin (P<0.02), luteolin (P<0.02), quercetin (P<0.001) and kaempferol 
(P<0.001) but no significant effect of α-naphthoflavone,  β-naphthoflavone, 
genistein, daidzein, taxifolin, PD98059 and aminogenitein on BACE-1 activity 
(P>0.05). 
 
 
Figure 4. (A) Graph showing the docking scores (Observed Glide XP score) 
correlation for the flavonoids between two crystal structures for BACE-1 
(2B8L and 2QMF). The Different flavonoids used in this study are indicated on 
the graph by the first two letters as bolded here: Genistein,  Quercetin, 
Taxifolin,  Kaemferol,  PD98059,  Luteolin,  Apigenin,  Daizein, 
Aminogeneistein,  alpha- and beta-Napthofalvone. No significant correlation 
(P>0.1) was observed between the two scores. In addition no correlation 
between the different docking scores and the amount of BACE-1 inhibition 
induced by flavonoids was observed showing that docking simulations do not 
predict accurately the affinity of flavonoids for the BACE-1 catalytic site. (B)  
Overlay of several different BACE-1 PDB structures revealing flexible loops 
(Loop1 and Loop2) in the active site pocket. Different ligand binding sites 
(using the following PDB structures: 2B8L, 2QMF, 3CIB, 3L5F, 3KMX) in the 
BACE-1 catalytic site are indicated by space fill dot representation. The active 
site aspartyl residues (Asp 32 and Asp 228) are represented in red space fill in 
the left. (C) Docking of kaemferol to BACE-1 structures. Overlay of crystal 
structure of BACE-1 from PDB file 2B8L (brown ribbon) and 2QMF (green 
ribbon) along with the top ranked docked pose of kaemferol. Left Side is a 
zoom of the active site showing differences in the docking orientation of 
kaempferol in 2B8L (ligand represented by pink sticks) and 2QMF (white 
sticks).  (D) Docking of quercetin to BACE-1 structures. Overlay of crystal 
structure of BACE-1 from PDB file 2B8L (brown ribbon) and 2QMF (green 
ribbon) along with top ranked docked pose of quercetin. Left Side is a zoom of 
the active site showing differences in the docking orientation of quercetin in 
2B8L (ligand represented by pink sticks) and 2QMF (white sticks). 
 
Results: 
Effect of flavonoids on Aβ, sAPPβ and sAPPα production: 
The impact of flavonoids on Aβ production was evaluated using 7W CHO cells 
overexpressing wild-type human APP. Following 24 hours of treatment with a 
dose range of flavonoids, the amount of human Aβ1-40 and Aβ1-42 in the 
culture media surrounding the 7W CHO cells was measured by ELISAs. A 
dose dependent inhibition of Aβ1-40 and Aβ1-42 production was observed for 
β-naphtoflavone, aminogenistein, luteolin, apigenin, quercetin, acacetin and 
PD98059 whereas genistein, α-naphtholavone, kaempferol baicalein, daidzein 
and taxifolin were inefficient for the dose range tested (Figure 1). The 
calculated IC50 for Aβ1-40 and Aβ1-42 were as follows for the most potent 
flavonoids identified; β-naphtoflavone (0.9 and 1.1 μM)<aminogenistein (5.7 
and 5.8 μM)<luteolin (6.5 and 8.8 μM)<apigenin (7.1 and 10.8 μM)<quercetin 
(10.2 and 10.2 μM).  Interestingly, a statistically significant correlation was 
observed between Aβ1-40 and Aβ1-42 values showing that active flavonoids 
are inhibiting Aβ1-40 and Aβ1-42 with the same potency (Figure 1C).  
 
 
Figure 5: Graphs representing the correlation between the inhibition of BACE-
1 activity observed in a cell free assay and the inhibition of Aβ1-40 (A) and 
Aβ1-42 (B) production in whole cells for the different flavonoids tested. Only a 
weak correlation was observed between Aβ production and BACE-1 inhibition 
(Pearson correlation coefficient=0.471; P<0.05). 
 
We next investigated the effects of flavonoids on sAPPβ and sAPPα secretion 
by 7W CHO cells. None of the flavonoids tested appear to stimulate sAPPα 
production suggesting that these compounds do not stimulate the α-secretase 
cleavage of APP (Figure 2). Among the flavonoids tested, quercetin, 
kaempferol, luteolin, apigenin and β-naphtoflavone appear to reduce sAPPβ 
production suggesting an inhibition of the β-cleavage of APP (Figure 2). We 
did not observe a significant impact of PD98059 and aminogenistein (at 10 and 
25 μM) on sAPPβ production, however a reduction in sAPPβ secretion was 
observed with a 50 μM dose of PD98059 but not for aminogenistein, daidzein, 
genistein and aminogenistein (Figure 2) suggesting that among the flavonoids 
tested only luteolin, apigenin, quercetin, β-naphthoflavone, taxifolin, 
kaempferol and PD98059 impact the β-cleavage of APP. We analyzed the BIOINFORMATION  open access 
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effect of some of the flavonoids on APP C-terminal fragments and observed 
that daidzein, aminogenistein and genistein which were unable to inhibit 
sAPPβ production do not inhibit APP-CTFβ generation, and to the contrary 
induce an accumulation of APP-CTFα and CTFβ suggesting inhibition of  the 
γ-secretase cut (Figure 2). A decreased APP-CTFβ production as well as an 
inhibition of sAPPβ secretion was observed for luteolin, quercetin, apigenin 
and kaempferol (Figure 2) suggesting that these flavonoids lower Aβ 
production by impacting the β-cleavage of APP. 
 
 
Figure 6: (A) Dose dependent inhibition of NFκB activity by Aβ lowering 
flavonoids. HEK293 cells stably expressing an NFκB luciferase reporter 
construct were co-treated with 20 ng/ml of TNFα and different doses of the 
flavonoids for 3 hours before measuring NFκB luciferase activity. ANOVA 
reveals a significant main effect of the flavonoid treatments (P<0.001) and of 
the doses used (P<0.001) on NFκB activity. Post-hoc comparisons show 
statistically significant differences between the control conditions and the 
treatments with kaempferol, quercetin, luteolin, apigenin and acacetin 
(P<0.001) on NFκB activity. Graphs representing the correlation between the 
inhibition of NFκB activity and Aβ1-40  (B) and Aβ1-42  (C) production 
observed for the different flavonoids tested.  A strong correlation between Aβ 
values and the amount of NFκB inhibition induced by flavonoids was observed 
(Pearson correlation coefficient=0.872; P<0.001). 
 
 
Figure 7: Effect of daidzein, apigenin, luteolin and quercetin on BACE-1 
transcription in human neuronal SH-SY5Y cells. BACE-1 transcription was 
quantified by RT-PCR in SHSY cells following treatment with flavonoids for 
30 minutes in presence and abscence of 20 ng/ml of TNFα. A strong induction 
of BACE-1 mRNA was observed in SH-SY5Y cells challenged with the NFκB 
inducer TNFα and an approximate 10 fold reduction in BACE-1 transcription 
was observed following treatments with apigenin, luteolin and quercetin 
showing that these flavonoids can mitigate BACE-1 expression induced by 
NFκB stimulation. No inhibition of TNFα induced BACE-1 transcription was 
observed with daidzein. ANOVA reveals a statistically significant main effect 
of TNFα (P<0.001), apigenin (P<0.001), luteolin (P<0.001) and quercetin 
(P<0.001) on BACE-1 mRNA level but no significant main effect of daidzein 
(P=0.323). Post-hoc comparisons show significant differences between TNFα 
and TNFα+apigenin (P<0.001), TNFα+luteolin (P<0.001) or TNFα+quercetin 
treatments (P<0.001) but no statistically significant difference between TNFα 
and TNFα+daidzein (P=0.805) treatments on BACE-1 mRNA level. 
 
Effects of flavonoids on BACE-1 activity: 
As many of the flavonoids tested appear to inhibit the β-cleavage of APP, we 
determined whether these flavonoids were direct inhibitors of the β-secretase 
(BACE-1) using a chemoluminescent cell free assay. We selected a 
chemoluminescent assay over a fluorescent based assay for measuring BACE-1 
activity since flavonoids are fluorescent (data not shown) and may interfere 
with the detection of BACE-1 activity by fluorescence. Among the flavonoids 
tested, baicalein appears the most potent for inhibiting BACE-1 activity with an 
IC50 around 10 μM  (Figure 3), however this compound is unable to 
significantly lower Aβ or sAPPβ production in whole cells (Figure 2). 
Luteolin, quercetin, kaempferol and apigenin dose dependently inhibited 
BACE-1 activity (Figure 3). Overall, the flavonoids tested appear weak 
inhibitors of BACE-1 activity in the cell free assay and the calculated IC50 
values were as follows; baicalein (10.2 μM)<kaempferol (27.7 μM)<quercetin 
(30.2 μM)<apigenin (34.2 μM)<luteolin (56.5 μM). To further evaluate the 
possible interaction of the flavonoids with BACE-1, we performed in silico 
docking simulations. The results of our docking experiments along with the 
Glide XP score is summarized in Table 1. We observed that the independent 
docking experiments based on two X-ray structures gave different rank orders 
of the flavonoids tested. As such, we observed a correlation coefficient of 0.33 
(p =0.12) showing no significant relationship between the Glide XP score of 
the docked flavonoids from the two different docking experiments (Figure 4). 
We further aligned the docked structure of flavonoids from the different 
docking experiments and found that the docked poses do not align. We 
observed that the highest docking score difference was for apigenin which had 
a Glide XP score of -9.01 while docking to 2B8L and -3.18 while docking to 
2QMF.  The best score among flavonoids observed while docking to 2B8L was 
for taxifolin (XP score -10.49) and worst for daizein (XP score -2.91).  While 
docking flavonoids to 2QMF, we found that the best score was observed for 
baicalein (-8.81) and the worst for apigenin (-3.18). Based on the observed 
BACE-1 IC50 in a cell free assay, we found that the docking experiment with 
2QMF had a better score for active flavonoids that inhibited BACE-1 at sub-
micromolar range.  Overall the flavonoids tested appear to be only weak 
BACE-1 inhibitors. In addition, only a weak correlation between the inhibition 
of BACE-1 activity and the inhibition of Aβ production by flavonoids in whole 
cells (Figure 5) was observed and their IC50 for inhibiting BACE-1 activity in a 
cell free assay is higher than their IC50 for inhibiting Aβ production in whole BIOINFORMATION  open access 
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cells suggesting these compounds mitigate Aβ production via additional 
mechanisms independently of direct BACE-1 inhibition. 
 
Effect of flavonoids on NFκB activity and BACE-1 transcription: 
We next investigated the effect of flavonoids on NFκB activity since 
flavonoids are known to display anti-inflammatory properties [16] and since we 
have shown previously that compounds of unrelated structure that inhibit 
NFκB activation can lower Aβ production by targeting the β-cleavage of APP 
[17, 18]. We observed that all of the flavonoids unable to significantly lower 
Aβ level in whole cells for the dose range tested (PD98059, taxifolin, genistein, 
daidzein and baicalein) were also unable to reduce NFκB activation induced by 
TNFα, whereas Aβ and APPsβ lowering flavonoids (kaempferol, quercetin, 
acacetin, apigenin and luteolin) dose dependently inhibited NFκB activation 
(Figure 6). Interestingly, we found a strong correlation between the amount of 
NFκB inhibition and the level of Aβ1-40 and Aβ1-42 inhibition for the 
different doses of the flavonoids tested, suggesting the Aβ lowering activity of 
the flavonoids is mediated via NFκB  (Figure 6). We next investigated the 
possible impact of daidzein, apigenin, luteolin and quercetin on BACE-1 
transcription using human neuronal SHSY cells and confirmed that NFκB 
lowering flavonoids (apigenin, luteolin and quercetin) inhibit BACE-1 
transcription stimulated by TNFα whereas daidzein, which does not 
significantly inhibit NFκB activity, does not affect BACE-1 transcription 
(Figure 7). 
 
Discussion: 
Several studies have revealed that natural flavonoids can reduce Aβ 
neurotoxicity [19-21] possibly via an antioxidative mechanism and inhibition 
of Aβ oligomerization [22]. In addition, several flavonoids have been shown to 
lower brain Aβ accumulation in transgenic mouse models of AD [23, 24]. 
Flavonoids have been proposed to act as BACE-1 inhibitors, the rate limiting 
enzyme responsible for the production of Aβ peptides [12, 25]. In our study, 
some of the Aβ lowering flavonoids that we tested decreased sAPPβ 
production suggesting an inhibition of the β-cleavage of APP. However, these 
flavonoids only weakly inhibited BACE-1 activity in a cell free assay and we 
found only a weak correlation between their effect on BACE-1 activity and 
their ability to lower Aβ in whole cells suggesting their Aβ lowering properties 
are mediated principally via other mechanisms. We also investigated the 
binding of flavonoids to the BACE-1 catalytic site employing docking 
simulations. Careful mining of the Protein Data Bank (PDB) for BACE-1 
revealed that there are 144 entries including apo and complexed structures with 
several different inhibitors. When we analyzed these structures using a 
molecular visualization tool, we observed that the active site of BACE-1 
possesses a high conformational flexibility upon ligand binding. The active site 
consists of aspartyl residues (32 and 228) encompassed by two highly flexible 
loop regions (Loop1: 9-13 KSGQG and Loop2: 71-74 YTQG) that undergo 
both side chain and backbone rearrangements. For example, in the structure 
2B8L the SER10 and its corresponding residue SER71 in the structure 
2QMFA, the distance between the backbone atom C-α is 6.83 Å whereas the 
distance between the side chain atom O-γ is 7.68 Å. The distance between 
2B8L:72THR and 3KMXA:133THR for CG2 atom is 5.74 Å and between the 
backbone C-α atoms is 4.38 Å. The active site pocket is plastic and different 
structures can be aligned to understand conformational changes due to induced 
fitting of the ligand. BACE-1 possesses a large active site pocket typical of 
aspartyl proteases and further adopts conformational changes  upon ligand 
binding that may include both side-chain rearrangement and backbone 
movement of residues in the active site [26-28]. Due to this fact, docking 
studies do not adequately reproduce ligand binding and may possibly over or 
under rank a ligand upon docking resulting in false positives. In our study, we 
used two different structures for BACE-1 and performed multiple docking 
studies. We observed that as a function of the different structures selected for 
BACE-1, the docking score/rank for the flavanoids was different. As a matter 
of fact, we found no correlation between the observed IC50 for BACE-1 
inhibition in the cell-free assay and the Glide XP Score in the docking 
experiments. Energetic calculations from our BACE-1 docking studies also 
reveal that the flavonoids only weakly bind the BACE-1 catalytic site; in 
agreement with the weak inhibition of BACE-1 activity we observed with 
flavonoids in a BACE-1 cell free assay. Docking studies of BACE-1 do not 
adequately reproduce the native structure when ligands are cross-docked and 
hence further studies that combine docking with Monte Carlo/Molecular 
Dynamics methods may be required [29]. Our data suggest the Aβ lowering 
flavonoids we tested are only poor BACE-1 inhibitor and must therefore 
regulate Aβ production in whole cells by other mechanisms. This conclusion is 
different from past studies [12] in which docking results on a single BACE-1 
structure were presented as evidence to support the hypothesis that flavonoids 
directly inhibit BACE-1 activity explaining their Aβ lowering properties in 
whole cells. Using docking experiments with  two different crystal structures 
for BACE-1, we demonstrate that the docking score of flavonoids is different 
for the two BACE-1 structures tested and do not correlate with the inhibition of 
BACE-1 activity observed with flavonoids in a cell free assay . It is therefore 
inaccurate to classify active from inactive flavonoids as BACE-1 inhibitors by 
simply using docking simulations alone. The Aβ lowering activity of 
flavonoids cannot be explained solely by their effect on BACE-1 activity. We 
found a lack of correlation between the amount of BACE-1 inhibition observed 
and the ability of the compounds to lower Aβ production in whole cells. In 
addition, their IC50 for inhibiting BACE-1 activity in a cell free assay was 
higher than their IC50 for inhibiting Aβ in whole cells suggesting that additional 
mechanisms besides direct BACE-1 inhibition also contribute to their Aβ 
lowering properties. We assessed the impact of flavonoids on NFκB activation 
since we have previously identified that compounds inhibiting NFκB activation 
can prevent the β-cleavage of APP and Aβ production [18]. We observed a 
strong correlation between the NFκB inhibition potency of the flavonoids and 
their ability to inhibit Aβ production suggesting that the preponderant 
mechanism responsible for the Aβ lowering properties of the flavonoids is 
related to their effect on NFκB activation. Interestingly, many flavonoids are 
known to inhibit tyrosine kinases and hence may regulate NFκB activity via 
their inhibitory action on multiple tyrosine kinases upstream of NFκB. NFκB 
has been shown previously to regulate the production of Aβ by regulating the 
β-cleavage of APP [18]. Others studies have shown that NFκB inhibition can 
directly regulate BACE-1 expression level [14, 30-32]. We effectively 
observed that apigenin, luteolin and quercetin inhibit BACE-1 transcription in 
human neuronal SHSY cells.  
 
Conclusion: 
Altogether our data suggest a multimodal mechanism of action of flavonoids 
towards Aβ production as the direct inhibition of BACE-1 activity by 
flavonoids appears to only marginally account for their Aβ lowering properties. 
We suggest that the Aβ lowering properties of flavonoids are mainly mediated 
via their effect on NFκB signaling which in turn affects the regulation of 
BACE-1 expression.  
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Supplementary material: 
 
Table 1: Summary of docking scores for different flavonoids using two different crystal structures for BACE-1 (2B8L and 2QMF). Compounds were ranked as a 
function of their IC50 for BACE-1 activity. A weak docking score was observed showing that flavonoids have a low affinity for the BACE-1 catalytic site.  
Compound plC50  Glide  XP 
Score (2B8L) 
Glide XP 
Score (2QMF) 
Ranking 
Based on 
plC50 
Ranking Based 
on 2B8L 
Docking 
Ranking 
Based on 
2QMF 
Baicalein -1  -5.34  -8.81  1  7  1 
Kaemferol -1.44  -8.42  -7.11  2  4  3 
Quercetin -1.48  -9.19  -8.04 3  2 2 
Apigenin -1.53 -9.01 -3.18 4  3  13 
Luteolin -1.75 -4.2  -5.37  5  10  6 
Daizein -1.91  -2.91  -4.66  6  12  9 
Genistein -1.94 -3.57 -5.23 7  11 8 
PD98059 -2.24 -5.55 -3.79 8  6  10 
β-napthoflavone  -2.26 -4.77 -3.54 9  8  11 
Taxifolin -2.35  -10.49 -5.84  10  1 4 
α-napthoflavone  -2.83  -1.07  -3.44 11  13 12 
Acacetin -5.7  -4.27  -5.69  12  9  5 
Aminogenistein -5.7  -6.75  -5.36  13  5  7 
 
 